Summary & Overview
HCPCS J1599: Intravenous Immune Globulin, Liquid, 500 mg
HCPCS Level II code J1599 describes an intravenous immune globulin (non-lyophilized liquid) product billed per 500 mg unit. IVIG therapies are used across multiple immune-mediated conditions and high-cost biologic infusions have significant implications for facility operations, prior authorization workflows, and national payer reimbursement policies. Clear coding for unit-based IVIG products supports accurate utilization tracking and claim adjudication.
Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise national perspective on coding and billing context for J1599, including typical sites of service and the clinical service type. The publication also outlines what readers can expect from accompanying materials: national benchmarks and utilization patterns where available, recent policy and coverage considerations affecting IVIG administration and billing, and clinical context about IVIG as an infusion therapy.
Data not available in the input for payer-specific rates, associated taxonomies, ICD-10 pairings, related codes, and line-item service details is noted where relevant. This summary is intended for revenue cycle, coding, and policy professionals seeking a focused briefing on HCPCS Level II code J1599 in the national payer environment.
Billing Code Overview
HCPCS Level II code J1599 represents an intravenous immune globulin (liquid), unit of 500 mg for injection. This code designates administration of a non-lyophilized (liquid) formulation of immune globulin given intravenously and is reported per 500 mg unit.
Service type: Intravenous immune globulin infusion (IVIG)
Typical site of service: Outpatient infusion center, hospital outpatient department, or physician office infusion suite
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with primary or secondary immunodeficiency, chronic inflammatory neuropathy, or certain autoimmune disorders who requires replacement or immunomodulatory therapy administered intravenously. The patient arrives at an outpatient infusion center or hospital outpatient department for administration of intravenous immune globulin (IVIG) using billing code J1599 for a 500 mg unit of liquid (non-lyophilized) immune globulin not otherwise specified. The clinical workflow includes verification of diagnosis and prior authorization, baseline vital signs and weight-based dose calculation, venous access placement (peripheral or central), infusion pump setup with appropriate infusion-rate ramping per product labeling, monitoring for infusion reactions (vital signs, observation for hypersensitivity), management of adverse effects (e.g., premedication or rate adjustment), documentation of lot numbers and batch identifiers, and post-infusion assessment for disposition. Typical sites of service are outpatient infusion centers, hospital outpatient departments, and skilled nursing facilities when clinically indicated. Common patient scenarios include replacement therapy for primary immunodeficiency, treatment for chronic inflammatory demyelinating polyneuropathy (CIDP), prophylaxis or treatment for select antibody-mediated conditions, and adjunctive therapy for certain autoimmune or hematologic disorders.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |